Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.95 |
| ▸ | TTR | P02766 | 5/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | MEN1 | O00255 | 4/20 | 0.95 |
| ▸ | MAPT | P10636 | 4/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.95 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.95 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.95 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.95 |
| ▸ | TP53 | P04637 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.95 |
| ▸ | HPGD | P15428 | 3/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resveratrol SCHEMBL22469907 | 1.00 | PTGS1 (0.95) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL2300985 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL17629801 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL15106855 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL19426 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL3704258 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL20164915 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL19425 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Cis-Resveratrol SCHEMBL1931746 | 0.97 | PTGS1 (1.00) | PTGS1KDM4ETTRLMNAMEN1 | |
| Resveratrol SCHEMBL31096991 | 0.95 | PTGS1 (0.95) | PTGS1KDM4ETTRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198320-A1 | METHODS AND COMPOSITIONS RELATED TO ENHANCING RETROVIRAL VECTOR ENTRY AND INTEGRATION IN HOST CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-01 | — | — | WO | claimed |
| US-12410209-B2 | Modified glucocorticoids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4362951-A1 | MODIFIED GLUCOCORTICOIDS | Board of Regents, The University of Texas System (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278289-A1 | MODIFIED GLUCOCORTICOIDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220411460-A1 | MODIFIED GLUCOCORTICOIDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-12-29 | — | — | US | disclosed |
| CN-115243705-A | Novel transduction enhancers and uses thereof | 苏黎世大学 | 2022-10-25 | — | — | CN | disclosed |
| WO-2020198320-A1 | METHODS AND COMPOSITIONS RELATED TO ENHANCING RETROVIRAL VECTOR ENTRY AND INTEGRATION IN HOST CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20160220542-A1 | SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITISATION OF TUMOR CELLS | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20130171104-A1 | SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITIZATION OF TUMOR CELLS | UNIVERSITAETSKLINIKUM FREIBURG (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410209-B2 | Modified glucocorticoids | NR3C1, NR3C2, NR5A1 | PTGS1 156/4885KDM4E 753/4885TTR 392/4885 |
| US-20220411460-A1 | MODIFIED GLUCOCORTICOIDS | NR3C1, NR3C2, NR5A1 | PTGS1 156/4885KDM4E 753/4885TTR 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.